Inhaled therapy for the management of perioperative pulmonary hypertension

C. Thunberg, S. Morozowich, Harish Ramakrishna

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.

Original languageEnglish (US)
Pages (from-to)394-402
Number of pages9
JournalAnnals of Cardiac Anaesthesia
Volume18
Issue number3
DOIs
StatePublished - Jul 1 2015

Fingerprint

Vasodilator Agents
Pulmonary Hypertension
Pulmonary Artery
Nitric Oxide
Pressure
Inhalation
Milrinone
Iloprost
Sodium Nitrite
Phosphodiesterase Inhibitors
Nitroglycerin
Nitroprusside
Epoprostenol
Therapeutics
Hypotension
Prostaglandins
Lung
Pharmaceutical Preparations

Keywords

  • Nitric oxide-donating drugs
  • Phosphodiesterase inhibitors
  • Prostanoids
  • Prototypical inhaled pulmonary-specific vasodilator

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Inhaled therapy for the management of perioperative pulmonary hypertension. / Thunberg, C.; Morozowich, S.; Ramakrishna, Harish.

In: Annals of Cardiac Anaesthesia, Vol. 18, No. 3, 01.07.2015, p. 394-402.

Research output: Contribution to journalArticle

@article{393594c3510e4f839b7aa68f643ede1e,
title = "Inhaled therapy for the management of perioperative pulmonary hypertension",
abstract = "Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.",
keywords = "Nitric oxide-donating drugs, Phosphodiesterase inhibitors, Prostanoids, Prototypical inhaled pulmonary-specific vasodilator",
author = "C. Thunberg and S. Morozowich and Harish Ramakrishna",
year = "2015",
month = "7",
day = "1",
doi = "10.4103/0971-9784.159811",
language = "English (US)",
volume = "18",
pages = "394--402",
journal = "Annals of Cardiac Anaesthesia",
issn = "0971-9784",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Inhaled therapy for the management of perioperative pulmonary hypertension

AU - Thunberg, C.

AU - Morozowich, S.

AU - Ramakrishna, Harish

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.

AB - Patients with pulmonary hypertension (PH) are at high risk for complications in the perioperative setting and often receive vasodilators to control elevated pulmonary artery pressure (PAP). Administration of vasodilators via inhalation is an effective strategy for reducing PAP while avoiding systemic side effects, chiefly hypotension. The prototypical inhaled pulmonary-specific vasodilator, nitric oxide (NO), has a proven track record but is expensive and cumbersome to implement. Alternatives to NO, including prostanoids (such as epoprostenol, iloprost, and treprostinil), NO-donating drugs (sodium nitroprusside, nitroglycerin, and nitrite), and phosphodiesterase inhibitors (milrinone, sildenafil) may be given via inhalation for the purpose of treating elevated PAP. This review will focus on the perioperative therapy of PH using inhaled vasodilators.

KW - Nitric oxide-donating drugs

KW - Phosphodiesterase inhibitors

KW - Prostanoids

KW - Prototypical inhaled pulmonary-specific vasodilator

UR - http://www.scopus.com/inward/record.url?scp=84936766628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936766628&partnerID=8YFLogxK

U2 - 10.4103/0971-9784.159811

DO - 10.4103/0971-9784.159811

M3 - Article

VL - 18

SP - 394

EP - 402

JO - Annals of Cardiac Anaesthesia

JF - Annals of Cardiac Anaesthesia

SN - 0971-9784

IS - 3

ER -